Date: October 12, 2026
Investment in Subsidiary
Dr. Lal PathLabs Limited has made a further investment in its wholly-owned subsidiary, PathLabs Unifiers Private Limited (PUPL), by subscribing to equity shares of PUPL on October 12, 2026.
Investment Details
- Investment Amount: Not exceeding INR 30.3 Crores
- Consideration Type: Cash Consideration
- Transaction Status: Completed
- Regulatory Approvals: Not Applicable
Purpose of Investment
The investment is intended to fund PUPL's acquisition of the remaining 30% equity stake in CentraPath Labs Private Limited (CPL), which is currently a subsidiary of PUPL. Post this acquisition, CPL will become a Wholly Owned Subsidiary of PUPL.
Subsidiary Information
PathLabs Unifiers Private Limited (PUPL)
- Incorporation Date: December 12, 2018
- Location: National Capital Territory Delhi
- Business: Healthcare/ Diagnostics Services
- Ownership Status: Continues to remain a Wholly Owned Subsidiary of Dr. Lal PathLabs Limited
Financial Performance of PUPL:
- FY 2026 Turnover: ₹7.23 Crores
- FY 2025 Turnover: ₹7.10 Crores
- FY 2024 Turnover: ₹7.28 Crores
Transaction Nature
- Related Party Transaction: Yes, as PUPL is a wholly-owned subsidiary
- Transaction Basis: Arm's length basis
- Industry: Healthcare/ Diagnostics Services